ADC Therapeutics posts corporate presentation highlighting Zynlonta growth opportunity in B-cell lymphomas
ADCT•Zynlonta Phase 3 LOTIS-5 data highlighted
- ADC Therapeutics highlighted Phase 3 LOTIS-5 data for ZYNLONTA plus rituximab in 2L+ relapsed or refractory DLBCL.
- Trial met primary endpoint: PFS by independent review HR 0.73; p 0.0084; median PFS 6.14 months vs 4.73 months.
- IRC overall response 58% vs 45%; complete response 40% vs 27%; median duration of complete response 16.82 months vs 12.25 months.
- Overall survival showed no detriment: HR 0.96; median OS 12.19 months vs 12.16 months.
- Grade 5 TEAEs 13.2% vs 4.6%; serious TEAEs 49% vs 34.5%; withdrawals 25.5% vs 9.1%.
